RxDoctor Payments Data

Eiman Nabi, MD

Gastroenterology · Washington, DCNPI 1588952659

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.

$6,683in general payments, 2019–2025

Across 341 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$648
  • Pfizer$568
  • Bristol Myers Squibb$419
  • Johnson & Johnson$387
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$6,668100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,683 in reported general payments places this provider in the 70th percentile of 77 gastroenterology providers in District of Columbia.

See all gastroenterology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$112,552
Medicare patients
360
Services billed
846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide21$24,845
Dexlansoprazole DrDexlansoprazole28$11,137
Lubiprostone38$8,084
Mesalamine25$6,878
Omeprazole186$3,159
CholestyramineCholestyramine (With Sugar)18$2,436
Lansoprazole86$2,262
Esomeprazole Magnesium29$1,983
Famotidine93$1,630
Colestipol Hcl20$1,611
Ursodiol13$1,523
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,455
Pantoprazole Sodium77$1,224
Dicyclomine Hcl65$690
Ondansetron Hcl14$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,113$24,84521 claims
SandozLansoprazole$33$2,26286 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 gastroenterology providers in District of Columbia.

Other gastroenterology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →